Russell Greig Leaves GSK's SR One
This article was originally published in The Pink Sheet Daily
Executive Summary
The managing partner and president of GSK's corporate venture group appears to have quietly moved on.
You may also be interested in...
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.
Venture Data Continues To Haunt The Biotech Landscape
Venture firms suffered fundraising woes last year, and a handful of biopharma funds stopped investing. It could get worse.